The role of the PIC/S organization in the pharmaceutical industry was noted, the main aspects and place of inspection activities in the production of medicines were determined, the general classification of incompliances, as well as the main methods and tools for risk assessment were considered.
INTRODUCTION
Aseptic production is one of the most difficult production methods in the pharmaceutical industry, since it is necessary to maintain sterility and apyrogenity throughout the production process, due to the lack of a final sterilization stage. More and more drugs are produced under aseptic conditions. In the territory of the Russian Federation, the main document in the field of requirements for the production of sterile medicines, including those manufactured under aseptic conditions, is Appendix 1 of the Rules of Good Manufacturing Practice, which complies with the EU GMP Rules and GMP PIC\S.
On August 28, 2017, the Ministry of Industry and Trade of the Russian Federation submitted a preliminary application for Russia's entry into PIC/S, which implies the adoption and consent of Russia to the requirements of GMP PIC/S. Currently, the EU and PIC\S are actively discussing a draft update of Appendix 1 to the GMP PIC\S rules, which was published on December 20, 2017 for public discussion [1] [2] [3] [4] [5] .
II. EXPERIMENTAL Changes in Appendix 1 are aimed at detailing the current statements, eliminating ambiguities and introducing new requirements. Thus, the changes will become an occasion for revising the current quality system at each enterprise engaged in the production of sterile medicines. That is why it is important to take preventive actions to identify inconsistencies of current practices and the organization of production with the requirements set forth in the draft Appendix 1. 
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Joining PIC\S requires a lot of actions on the part of the institutions regulating the production and circulation of medicines in the territory of the Russian Federation, among which, first of all, the harmonization of local regulatory requirements with international ones. Harmonization of the requirements of EU GMP Appendix No. 1 and Order No. 916 Appendix No. 1 is a priority, since the differences between the current version of Order No. 916 Appendix No. 1 and the draft Appendix No. 1 are significant and may affect the organization of production of sterile dosage forms.
Thus, a preventive analysis of the current conformity of production to the draft Appendix No. 1 will allow, by the time the updated version of Appendix No. 1 comes into force in Russia, to reduce the number of nonconformities, completely eliminate nonconformities, or develop a detailed plan for eliminating nonconformities depending on their priority.
The purpose of the study is to audit the operating production of sterile medicines for compliance with the requirements of the draft EU GMP Appendix 1 using a risk analysis. To develop a universal plan and audit protocol for the production of sterile medicines for compliance with the requirements of the draft GMP EU Annex 1.
In preparation for the audit, an audit plan and protocol was developed, as well as an algorithm for working with the audit protocol ( fig.1 and 2 ). In terms of audit, the most important steps are the preparatory phase and the immediate conduct of the audit. The audit protocol contains standard elements, such as the name of the document, version information and place in the enterprise documentation system. The basis of the protocol is an assessment table, which presents the clauses of the draft Annex No. 1, similar paragraphs of Annex No. 1 of the Rules of Good Manufacturing Practice of the Russian Federation and the fields for assessing compliance [4] . When working with the audit protocol, it was decided to divide all types of incompliance into incompliance that require modernization of manufacturing site for their elimination (including equipment purchase, redevelopment of premises, purchase and installation of sensors) and incompliances, to eliminate which it is necessary to work with the company's internal documentation. In accordance with this division of nonconformities, their criticality for production, for product quality and, as a result, patient health was evaluated.
Incompliances were assessed by FMEA risk analysis [6] . The FMEA method is designed to assess potential process failures, as well as their possible consequences on process results and / or product properties. The method is based on an understanding of the process and products. In FMEA, processes are divided into separate stages (stages, flowcharts). FMEA principles can be applied outside of project development at all stages of the product life cycle. 
III. RESULTS AND DISCUSSION
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Next important step was to estimate connection between total risk score and actions, which allow eliminating or at least mitigating discovered risk.
Risk Priority Number is calculated by the formula: RPN = S * P * D (table II) The audit revealed 30 inconsistencies, 19 moderate and 11 significant, the criticality of which was further assessed using risk analysis using the FMEA method. The risk caused by each of the deviations was quantified and recommendations for addressing incompliance were developed. For example, the inconsistency with paragraph 4.12, consisting in the lack of completeness of the clothes of an operator working in an aseptic zone, can be eliminated by reviewing the completeness of workwear and updating the SOP at the entrance to clean rooms (table III and IV) .
For every discovered in compliance recommendations were developed. During a repeated risk assessment, it was found that, taking into account the implementation of recommendations, most of the risks can be reduced to the level at which their adoption is possible, and critical risks can be reduced to a moderate level. Practical recommendations for elimination incompliances have been developed. As a result of a repeated risk assessment, it was found that the implementation of the recommendations will reduce the RPN of risks associated with the identified deviations to an acceptable level.
It is relevant to use developed audit plan and audit protocol when evaluating the operating manufacturing of sterile medicines. 
